<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT01722435</url>
  </required_header>
  <id_info>
    <org_study_id>ZIS-OST-PV3718</org_study_id>
    <nct_id>NCT01722435</nct_id>
  </id_info>
  <brief_title>Completion of OST - a Prospective Study</brief_title>
  <official_title>Completion of Substitution Treatment With Methadone/Levomethadone - a Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Asklepios Kliniken Hamburg GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr. Rainer Ullmann</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr. Sibylle Quellhorst</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dr. Jochen Brack</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Michael Klemperer</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gesine Hoeft</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Only limited information on the process of completing long-term opiate substitution treatment&#xD;
      (OST) with substances like methadone exist. Furthermore, systematic knowledge from scientific&#xD;
      studies is scarce, there are only few studies with respect to treatment completion or regular&#xD;
      termination (mainly catamnestic analyses). Studies by Nordt et al. (2004) or Nordt &amp; Stohler&#xD;
      (2006) show an estimated rate of 10% of patients per year who terminate OST by means of&#xD;
      tapering the substitution agent or changing into withdrawal treatment in specialized clinics.&#xD;
      It is state of the art that an indication for termination of OST has to be based on a common&#xD;
      agreement between the patient and the doctor. Furthermore, the patient should live in a&#xD;
      stable social situation and the state of health had markedly improved. Finally, the patient&#xD;
      has to be free of (illegal) drug use for at least 6 months and the individual aims of&#xD;
      treatment should have been reached (Vader et al. 2003).&#xD;
&#xD;
      The main objective of the prospective and explorative study is the systematic description of&#xD;
      the process of termination of OST. With a comparison between patients who complete OST&#xD;
      regularly and patients who terminate treatment prematurely (or are still in treatment)&#xD;
      predictors of positive termination of OST can be identified.&#xD;
&#xD;
      Patients treated with methadone or levomethadone of 5 general practitioners' practices and 2&#xD;
      specialized clinics who might be able to terminate OST during the next 12 months from the&#xD;
      doctors' perspective can take part in the study. In addition to baseline examination further&#xD;
      assessments take place every 3 months (i.e. after 3, 6, 9 and 12 months). The questionnaires&#xD;
      include state of health, well-being, social situation as well as drug and alcohol use.&#xD;
      Furthermore, the treating doctors are asked every 3 months to fill out questionnaires on&#xD;
      infections and other disorders, clinical characteristics, dosage process and drug use&#xD;
      (measured by urine samples).&#xD;
&#xD;
      Patients who will be successful in completing OST during the observational period will be&#xD;
      compared with the remaining cases.&#xD;
&#xD;
      Finally, a 6-month follow-up is planned in order to investigate the stability and maintenance&#xD;
      of the situation at month 12.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Completion of OST</measure>
    <time_frame>18 months</time_frame>
    <description>Regularly completion of OST, i.e. not being on opioid medication any more, during the study period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OST Drop-outs</measure>
    <time_frame>18 months</time_frame>
    <description>Participants dropped out of OST Treatment during the study period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Time to Complete OST</measure>
    <time_frame>18 months</time_frame>
    <description>Mean time of study participation (M, SD) until Treatment completion or end of study (after 18 months).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Time to Drop-out of OST</measure>
    <time_frame>18 months</time_frame>
    <description>Mean time of study participation (M, SD) until drop-out of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Time Staying in OST</measure>
    <time_frame>18 months</time_frame>
    <description>Mean time of study participation (M, SD) of patients who stayed in OST Treatment until end of study (after 18 months).</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">78</enrollment>
  <condition>Opioid Dependence</condition>
  <arm_group>
    <arm_group_label>OST completers</arm_group_label>
    <description>Patients who are likely to complete OST during the next 12 or 18 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Opiate Substitution Treatment</intervention_name>
    <arm_group_label>OST completers</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients in primary care setting (GPs) or specialized clinics likely to complete opiate&#xD;
        substitution treatment (OST) during the next 12 months.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  opioid dependence according ICD-10&#xD;
&#xD;
          -  Minimum age of 18 years&#xD;
&#xD;
          -  In OST with methadone or levomethadone&#xD;
&#xD;
          -  Expected or planned treatment completion during the next 12 months&#xD;
&#xD;
          -  Informed consent to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with planned hospitalisation during the next 12 months&#xD;
&#xD;
          -  Patients who are likely or it is save to assume that they will be incarcerated or&#xD;
             imprisoned during the next 12 months&#xD;
&#xD;
          -  Disability to take part in the study or follow the study conditions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens Reimer, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre for Interdisciplinary Addiction Research of Hamburg University</affiliation>
  </overall_official>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>November 2, 2012</study_first_submitted>
  <study_first_submitted_qc>November 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2012</study_first_posted>
  <results_first_submitted>June 3, 2014</results_first_submitted>
  <results_first_submitted_qc>August 5, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 22, 2014</results_first_posted>
  <last_update_submitted>October 1, 2019</last_update_submitted>
  <last_update_submitted_qc>October 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitätsklinikum Hamburg-Eppendorf</investigator_affiliation>
    <investigator_full_name>Prof. Dr. med. Jens Reimer</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>opioid dependence</keyword>
  <keyword>opiate substitution treatment</keyword>
  <keyword>methadone</keyword>
  <keyword>completion</keyword>
  <keyword>termination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opiate Alkaloids</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>OST Completers</title>
          <description>Patients who are likely to complete OST during the next 12 or 18 months&#xD;
Opiate Substitution Treatment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patients treated with methadone or levomethadone who were eligible for the study and consented to participate and qualified for treatment completion in the next 12 months.</population>
      <group_list>
        <group group_id="B1">
          <title>OST Completers</title>
          <description>The main objective of this prospective study was the description of the process of termination of opiate substitution treatment (OST). Patients in primary care setting (GPs) or specialized clinics likely to complete OST during the next 12 months were asked to fill out questionnaires every 3 months over a 12-months period and were followed up another 6 months later. Accordingly, the doctors documented their patients' state of health and provided an evaluation of their living situation every 3 months and at the end of treatment (or - if patients stayed in treatment - at the end of the 18-months study period).&#xD;
At the beginning of the study overall 1367 OST patients were treated in the 7 participating clinics and practices. 972 of them were treated with methadone or levomethadone. In line with the inclusion criteria, 97 patients were eligible for the study, 78 of them consented to participate in the study (8.0% of all patients treated with methadone or levomethadone).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="78"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.5" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lengths of OST before study entry</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92.9" spread="59.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Participants on specific medication</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>d,l-methadone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>levometahdone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>buprenorphine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Average dose of medication taken</title>
          <units>milligrams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>d,l-methadone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.8" spread="41.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>levomethadone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.6" spread="21.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>buprenorphine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.3" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Completion of OST</title>
        <description>Regularly completion of OST, i.e. not being on opioid medication any more, during the study period.</description>
        <time_frame>18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OST Completers</title>
            <description>Patients who are likely to complete OST during the next 12 or 18 months Opiate Substitution Treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Completion of OST</title>
          <description>Regularly completion of OST, i.e. not being on opioid medication any more, during the study period.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OST Drop-outs</title>
        <description>Participants dropped out of OST Treatment during the study period.</description>
        <time_frame>18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OST Completers</title>
            <description>Patients who are likely to complete OST during the next 12 or 18 months.</description>
          </group>
        </group_list>
        <measure>
          <title>OST Drop-outs</title>
          <description>Participants dropped out of OST Treatment during the study period.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Time to Complete OST</title>
        <description>Mean time of study participation (M, SD) until Treatment completion or end of study (after 18 months).</description>
        <time_frame>18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OST Completers</title>
            <description>Patients completed OST during 12 or 18 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Time to Complete OST</title>
          <description>Mean time of study participation (M, SD) until Treatment completion or end of study (after 18 months).</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="232" spread="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Time to Drop-out of OST</title>
        <description>Mean time of study participation (M, SD) until drop-out of treatment.</description>
        <time_frame>18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OST Drop-outs</title>
            <description>Patients dropped out of OST during 12 or 18 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Time to Drop-out of OST</title>
          <description>Mean time of study participation (M, SD) until drop-out of treatment.</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="315" spread="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Time Staying in OST</title>
        <description>Mean time of study participation (M, SD) of patients who stayed in OST Treatment until end of study (after 18 months).</description>
        <time_frame>18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Still in OST Completers</title>
            <description>Patients still in OST during the whole study period.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Time Staying in OST</title>
          <description>Mean time of study participation (M, SD) of patients who stayed in OST Treatment until end of study (after 18 months).</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="549" spread="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>OST Completers</title>
          <description>Patients who are likely to complete OST during the next 12 or 18 months Opiate Substitution Treatment</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof. Dr. Jens reimer</name_or_title>
      <organization>Centre for Interdisciplinary Addiction research of Hamburg University ZIS</organization>
      <phone>+4940741057900</phone>
      <email>reimer@uke.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT01722435
org study id: ZIS-OST-PV3718
nct id: NCT01722435
lead sponsor: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
has dmc: No
Only limited information on the process of completing long-term opiate substitution treatment
      (OST) with substances like methadone exist. Furthermore, systematic knowledge from scientific
      studies is scarce, there are only few studies with respect to treatment completion or regular
      termination (mainly catamnestic analyses). Studies by Nordt et al. (2004) or Nordt & Stohler
      (2006) show an estimated rate of 10% of patients per year who terminate OST by means of
      tapering the substitution agent or changing into withdrawal treatment in specialized clinics.
      It is state of the art that an indication for termination of OST has to be based on a common
      agreement between the patient and the doctor. Furthermore, the patient should live in a
      stable social situation and the state of health had markedly improved. Finally, the patient
      has to be free of (illegal) drug use for at least 6 months and the individual aims of
      treatment should have been reached (Vader et al. 2003).

      The main objective of the prospective and explorative study is the systematic description of
      the process of termination of OST. With a comparison between patients who complete OST
      regularly and patients who terminate treatment prematurely (or are still in treatment)
      predictors of positive termination of OST can be identified.

      Patients treated with methadone or levomethadone of 5 general practitioners' practices and 2
      specialized clinics who might be able to terminate OST during the next 12 months from the
      doctors' perspective can take part in the study. In addition to baseline examination further
      assessments take place every 3 months (i.e. after 3, 6, 9 and 12 months). The questionnaires
      include state of health, well-being, social situation as well as drug and alcohol use.
      Furthermore, the treating doctors are asked every 3 months to fill out questionnaires on
      infections and other disorders, clinical characteristics, dosage process and drug use
      (measured by urine samples).

      Patients who will be successful in completing OST during the observational period will be
      compared with the remaining cases.

      Finally, a 6-month follow-up is planned in order to investigate the stability and maintenance
      of the situation at month 12.
observational model: Cohort
time perspective: Prospective
measure: Completion of OST
time frame: 18 months
description: Regularly completion of OST, i.e. not being on opioid medication any more, during the study period.
measure: OST Drop-outs
time frame: 18 months
description: Participants dropped out of OST Treatment during the study period.
measure: Mean Time to Complete OST
time frame: 18 months
description: Mean time of study participation (M, SD) until Treatment completion or end of study (after 18 months).
measure: Mean Time to Drop-out of OST
time frame: 18 months
description: Mean time of study participation (M, SD) until drop-out of treatment.
measure: Mean Time Staying in OST
time frame: 18 months
description: Mean time of study participation (M, SD) of patients who stayed in OST Treatment until end of study (after 18 months).
arm group label: OST completers
description: Patients who are likely to complete OST during the next 12 or 18 months
intervention type: Drug
intervention name: Opiate Substitution Treatment
arm group label: OST completers
study pop: 
sampling method: Non-Probability Sample
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Jens Reimer, Professor
role: Principal Investigator
affiliation: Centre for Interdisciplinary Addiction Research of Hamburg University
responsible party type: Principal Investigator
investigator affiliation: Universitätsklinikum Hamburg-Eppendorf
investigator full name: Prof. Dr. med. Jens Reimer
investigator title: Prof. Dr.
mesh term: Opioid-Related Disorders
mesh term: Opiate Alkaloids
participant flow: 
baseline: 
outcome list: 
reported events: 
certain agreements: 
point of contact: 